Abstract | BACKGROUND: The prognostic importance of hemoglobin is controversial. We investigated the prognostic importance of baseline and in-treatment hemoglobin in the LIFE study. METHODS: RESULTS: U-shaped relations were observed between deciles of baseline hemoglobin and all-cause mortality and the composite end point. In univariate Cox models, baseline hemoglobin in the lowest gender-specific decile (women/men: <12.5/13.4 g/dL) was associated with all-cause mortality (hazard ratio [HR] 2.01, 95% CI 1.64-2.64) and the composite end point (HR 1.53, 95% CI 1.27-1.85, both P < .001), whereas hemoglobin in the highest gender-specific decile (women/men: > or =15.0/16.2 g/dL) was not. The decrease in hemoglobin was higher (P < .001) in patients allocated to losartan- (14.3-13.8 g/dL) versus atenolol-based treatment (14.3-14.0 g/dL). In Cox models with the same gender-specific definitions for high and low hemoglobin as time-varying covariates with adjustment for treatment allocation and established risk factors and diseases, hemoglobin in the lowest decile was associated with higher rates of all-cause mortality (HR 3.03, 95% CI 1.89-4.85, P < .001) and the composite end point (HR 1.36, 95% CI 1.08-1.71, P < .01), whereas hemoglobin in the highest decile was not. CONCLUSIONS: After adjusting for other risk factors, relatively low, but not high, hemoglobin during antihypertensive treatment was associated with higher incidence of all-cause mortality and the composite end point.
|
Authors | Michael Hecht Olsen, Kristian Wachtell, Gareth Beevers, Björn Dahlöf, Richard B Devereux, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Sverre E Kjeldsen, Ole Lederballe-Pedersen, Lars H Lindholm, Puneet Narayan, Markku S Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel |
Journal | American heart journal
(Am Heart J)
Vol. 157
Issue 1
Pg. 177-84
(Jan 2009)
ISSN: 1097-6744 [Electronic] United States |
PMID | 19081416
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic beta-Antagonists
- Antihypertensive Agents
- Hemoglobins
- Atenolol
- Losartan
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Aged
- Aged, 80 and over
- Antihypertensive Agents
(therapeutic use)
- Atenolol
(therapeutic use)
- Electrocardiography
- Female
- Hemoglobins
(analysis)
- Humans
- Hypertension
(blood, complications, drug therapy, mortality)
- Hypertrophy, Left Ventricular
(complications, diagnosis)
- Losartan
(therapeutic use)
- Male
- Middle Aged
- Prognosis
|